Eloxx Pharmaceuticals, Inc.: 5%+ holders

As of November 10, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Eloxx Pharmaceuticals, Inc. The largest reported stake is Domicilium Capital Partners LLC's, at 19.99%. 12 filings are on record since May 1, 2026 (Schedule 13G, June 17, 2026).

Aberdeen Group plc also filed stake reports on 12 other companies ↓

Sell to companies like Eloxx Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 400,000 · Sole dispositive: 0 · Shared dispositive: 400,000 · SCHEDULE 13G, 2026-08-14
• Filed 2026-08-14 · Holder: Srinivas Akkaraju · Percent: 9.9% · SCHEDULE 13G
• Filing 2026-07-27 · Reporting person: Aberdeen Group plc · Sole voting: 0 · Shared voting: 400,000 · Sole dispositive: 0 · Shared dispositive: 400,000 · SCHEDULE 13G, 2026-07-27
• Filing 2026-06-17 · Reporting person: Domicilium Capital Partners LLC · Sole voting: 0 · Shared voting: 854,973 · Sole dispositive: 0 · Shared dispositive: 854,973 · SCHEDULE 13G, 2026-06-17
• Filing 2026-06-17 · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 410,530 · Sole dispositive: 0 · Shared dispositive: 410,530 · SCHEDULE 13G, 2026-06-17

Eloxx Pharmaceuticals, Inc. has 12 Schedule 13D or 13G filings on record since 2026-05-01. 8 holders' latest filing reports 5% or more of common stock, $0.01 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Eloxx Pharmaceuticals, Inc. and the warning signs.

See Eloxx Pharmaceuticals, Inc.'s free Snapshot Watch Eloxx Pharmaceuticals, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Eloxx Pharmaceuticals, Inc. and the records around it.

Eloxx Pharmaceuticals, Inc. elsewhere on the record

• Leadership changes Jun 2026
• Who owns it

Companies that share a holder

• Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
• Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026), KALARIS THERAPEUTICS, INC. (May 2026)
• Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)

Want the whole picture on Eloxx Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Eloxx Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Eloxx Pharmaceuticals, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Eloxx Pharmaceuticals, Inc. by CUSIP 29014R301 and gives its principal executive office as P.O. BOX 274, ARLINGTON, MA 02476 (SCHEDULE 13G, 2026-08-14).

What the percentages are based on

As of June 9, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page.Raymond Debbane, SCHEDULE 13G, 2026-06-15

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.Srinivas Akkaraju, SCHEDULE 13G, 2026-08-14

Timeline

Swipe the table sideways to see every column.

Questions about who owns Eloxx Pharmaceuticals, Inc.

Who owns Eloxx Pharmaceuticals, Inc.?

On this page, 8 holders' latest ownership filings report 5% or more of Eloxx Pharmaceuticals, Inc.: Domicilium Capital Partners LLC (19.99%, Schedule 13G, filed 2026-06-17), Coastlands Capital LP (9.99%, Schedule 13G, filed 2026-06-17), Raymond Debbane (9.99%, Schedule 13G, filed 2026-06-15), Aberdeen Group plc (9.91%, Schedule 13G, filed 2026-07-27) and Nantahala Capital Management, LLC (9.91%, Schedule 13G, filed 2026-08-14); 3 more are listed above.

Who are the largest shareholders of Eloxx Pharmaceuticals, Inc.?

By the share each holder's latest filing reports, the largest holders of Eloxx Pharmaceuticals, Inc. on this page are Domicilium Capital Partners LLC (19.99%), Coastlands Capital LP (9.99%) and Raymond Debbane (9.99%).

When did Domicilium Capital Partners LLC buy into Eloxx Pharmaceuticals, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Domicilium Capital Partners LLC on this page is the Schedule 13G, filed 2026-05-04, reporting 18.6%; its latest, Schedule 13G filed 2026-06-17, reports 19.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Eloxx Pharmaceuticals, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Eloxx Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Eloxx Pharmaceuticals, Inc. is mentioned again
• Find former Eloxx Pharmaceuticals, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes